全文获取类型
收费全文 | 261篇 |
免费 | 50篇 |
国内免费 | 4篇 |
专业分类
基础医学 | 7篇 |
临床医学 | 12篇 |
内科学 | 207篇 |
皮肤病学 | 1篇 |
神经病学 | 2篇 |
外科学 | 25篇 |
预防医学 | 11篇 |
药学 | 50篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 10篇 |
2019年 | 17篇 |
2018年 | 28篇 |
2017年 | 12篇 |
2016年 | 19篇 |
2015年 | 19篇 |
2014年 | 14篇 |
2013年 | 15篇 |
2012年 | 15篇 |
2011年 | 15篇 |
2010年 | 10篇 |
2009年 | 5篇 |
2008年 | 14篇 |
2007年 | 16篇 |
2006年 | 9篇 |
2005年 | 13篇 |
2004年 | 13篇 |
2003年 | 7篇 |
2002年 | 7篇 |
2001年 | 15篇 |
2000年 | 9篇 |
1999年 | 11篇 |
1998年 | 3篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 1篇 |
1992年 | 1篇 |
1976年 | 1篇 |
1973年 | 1篇 |
排序方式: 共有315条查询结果,搜索用时 15 毫秒
1.
2.
B. Shen MD Z. Younossi MD B. Dolmatch MD J. Newman MD M. Henderson MD J. Ong MD T. Gramlich MD M. Yamani MD 《The American journal of gastroenterology》2000,95(9):2607-2607
3.
4.
5.
6.
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy 总被引:5,自引:0,他引:5
Pockros PJ Shiffman ML Schiff ER Sulkowski MS Younossi Z Dieterich DT Wright TL Mody SH Tang KL Goon BL Bowers PJ Leitz G Afdhal NH;PROACTIVE Study Group 《Hepatology (Baltimore, Md.)》2004,40(6):1450-1458
Anemia and decreased health-related quality of life (HRQL) are common in patients receiving combination therapy of interferon alfa (IFN) and ribavirin (RBV) for chronic hepatitis C virus (HCV) infection. In a randomized, prospective study evaluating the effectiveness of epoetin alfa in maintaining RBV dose, alleviating anemia, and improving HRQL in anemic (Hb < or = 12 g/dL) HCV-infected patients receiving combination therapy, patients receiving epoetin alfa had significant improvements in HRQL compared with placebo. In this study, 185 patients were randomized to 40,000 units of epoetin alfa subcutaneously weekly or placebo for an 8-week double-blind phase (DBP), followed by an 8-week open-label phase during which all patients received epoetin alfa. To further assess the impact of epoetin alfa on HRQL, post hoc analyses were conducted in the same patient population to compare the HRQL of these patients at randomization with norms of other populations, and to determine the critical relationship between hemoglobin (Hb) levels and HRQL. Mean HRQL scores of anemic HCV-infected patients receiving combination therapy at randomization were significantly lower than those of both the general population and patients who had other chronic conditions. Patients receiving epoetin alfa who had the greatest Hb increases from randomization to the end of the DBP also had the largest improvements in HRQL. Hb improvement was an independent predictor of HRQL improvement in these patients. In conclusion, epoetin alfa provided clinically significant HRQL improvement in HCV-infected patients receiving IFN/RBV therapy. 相似文献
7.
8.
Zobair Younossi Maria Stepanova Arun J. Sanyal Stephen A. Harrison Vlad Ratziu Manal F. Abdelmalek Anna Mae Diehl Stephen Caldwell Mitchell L. Shiffman Raul Aguilar Schall Bryan McColgan G. Mani Subramanian Robert P. Myers Andrew Muir Nezam H. Afdhal Jaime Bosch Zachary Goodman 《Journal of hepatology》2018,68(6):1365-1370
9.
Angelos Hatzakis Jeffrey V. Lazarus Evangelos Cholongitas Ricardo Baptista‐Leite Charles Boucher Cristian‐Silviu Busoi Sylvie Deuffic‐Burban Jagpreet Chhatwal Gamal Esmat Sharon Hutchinson Minerva‐Melpomeni Malliori Mojca Maticic Antons Mozalevskis Francesco Negro George A. Papandreou George V. Papatheodoridis Markus Peck‐Radosavljevic Homie Razavi Tatjana Reic Eberhard Schatz Nurdan Tozun Zobair Younossi Michael P. Manns 《Liver international》2020,40(2):260-270
The majority of people infected with chronic hepatitis C virus (HCV) in the European Union (EU) remain undiagnosed and untreated. During recent years, immigration to EU has further increased HCV prevalence. It has been estimated that, out of the 4.2 million adults affected by HCV infection in the 31 EU/ European Economic Area (EEA) countries, as many as 580 000 are migrants. Additionally, HCV is highly prevalent and under addressed in Eastern Europe. In 2013, the introduction of highly effective treatments for HCV with direct‐acting antivirals created an unprecedented opportunity to cure almost all patients, reduce HCV transmission and eliminate the disease. However, in many settings, HCV elimination poses a serious challenge for countries’ health spending. On 6 June 2018, the Hepatitis B and C Public Policy Association held the 2nd EU HCV Policy summit. It was emphasized that key stakeholders should work collaboratively since only a few countries in the EU are on track to achieve HCV elimination by 2030. In particular, more effort is needed for universal screening. The micro‐elimination approach in specific populations is less complex and less costly than country‐wide elimination programmes and is an important first step in many settings. Preliminary data suggest that implementation of the World Health Organization (WHO) Global Health Sector Strategy on Viral Hepatitis can be cost saving. However, innovative financing mechanisms are needed to raise funds upfront for scaling up screening, treatment and harm reduction interventions that can lead to HCV elimination by 2030, the stated goal of the WHO. 相似文献
10.